BMY Q3 2025 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$124B

Q3 2025 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$12.2B+2.8% YoY

Gross Profit

$8.8B71.9% margin

Operating Income

$3.6B29.8% margin

Net Income

$2.2B18.0% margin

EPS (Diluted)

$1.08

QoQ Revenue Growth

-0.4%

Cash Flow

Operating Cash Flow

$6.3B

Free Cash Flow

$6.0B

Stock-Based Comp.

$139M

Balance Sheet

Total Assets

$96.9B

Total Liabilities

$78.3B

Stockholders' Equity

$18.6B

Cash & Equivalents

$15.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12.2B	$11.9B	+2.8%
Gross Profit	$8.8B	$6.6B	+32.8%
Operating Income	$3.6B	$2.3B	+59.0%
Net Income	$2.2B	$1.2B	+81.8%

Revenue Segments

Eliquis

$3.7B31%

Opdivo

$2.5B21%

Orencia

$964M8%

Yervoy

$739M6%

Pomalyst/Imnovid

$675M6%

Reblozyl

$615M5%

Revlimid

$575M5%

Other Growth Brands

$514M4%

Breyanzi

$359M3%

Opdualag

$299M2%

Camzyos

$296M2%

Other Legacy Brands

$177M1%

Zeposia

$161M1%

Abecma

$137M1%

Sprycel

$119M1%

Sotyktu

$80M1%

Abraxane

$74M1%

Opdivo Ovantig

$67M1%

Krazati

$53M0%

Cobenfy

$43M0%

Geographic Segments

UNITED STATES

$8.3B97%

Other Region

$290M3%